ArticleJournal of pharmaceutical innovation2022
Analysis of the COVID-19 Vaccine Development Process: an Exploratory Study of Accelerating Factors and Innovative Environments.
Article in Journal of pharmaceutical innovation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Multi-perspectives systematic review on the applications of sentiment analysis for vaccine hesitancy.Computers in biology and medicine · 2021Pooled it
- COVID-19 vaccine uptake and predictors of hesitancy among healthcare workers in Côte d'Ivoire.Journal of public health in Africa · 2025Article
- Review
- Adverse events following COVID-19 vaccination: A comprehensive analysis of spontaneous reporting data in Ghana.PLOS global public health · 2024Article
- MicroRNAs Derived from Extracellular Vesicles: Keys to Understanding SARS-CoV-2 Vaccination Response in Cancer Patients?Cancers · 2023Review
- Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens.International journal of molecular sciences · 2023Review
- Attitude and Acceptance towards COVID-19 Booster Doses among Literacy Advantaged Population in Pakistan: A Cross-Sectional Study.Vaccines · 2023Article
- The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19.Journal of pharmaceutical innovation · 2023Article
- Vaccine Innovation Meta-Model for Pandemic Contexts.Journal of pharmaceutical innovation · 2023Article
- Public Health Management of the COVID-19 Pandemic in Australia: The Role of the Morrison Government.International journal of environmental research and public health · 2022Article
- Article
- US biopharmaceutical companies' stock market reaction to the COVID-19 pandemic. Understanding the concept of the 'paradoxical spiral' from a sustainability perspective.Technological forecasting and social change · 2022Article
- A statistical look at the COVID-19 vaccine development and vaccine policies.Frontiers in public health · 2022Article
- In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?World journal of hepatology · 2021Review
- Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks.Vaccines · 2021Article
- Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism.Vaccines · 2021Review
- Technology, engineering and innovations- Power buffers in the COVID driveline.....Indian journal of anaesthesia · 2021Article
- The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland.Vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The pace of the COVID-19 vaccine development process is unprecedented and is challenging the traditional paradigm of vaccinology science. The main pressure comes from the pandemic situation, but what makes it possible is a complex set of factors and innovative environments built along the times, which this manuscript aims to study. Methods: Through an exploratory study within the scope of innovation management, the present manuscript aims to identify and explore factors that are promoting this accelerated development scenario. The method comprises the monitoring of the strategies adopted by the developers and other stakeholders, as regulatory and humanitarian agencies, specific mechanisms from governments and non-governments bodies, and the background technology that has paved this pathway. Results: Technology-based and R&D strategy factors are the two main factors identified and explored herein. The breakthrough in the field of biotechnology and molecular biology is considered the main base-science that enables the rapid development of new vaccines. Additionally, new technological platforms can also be pointed out. Relating to R&D strategies, the parallelism of phases and adaptive clinical trials in consonance with regulatory agencies are the most relevant. Conclusions: The need to rapidly develop a vaccine against COVID-19 occurs at a time of great excitement in basic scientific understanding, as well as strategies learned in the past by industry and optimization of regulatory pathways. It is expected that these factors, arising from the global emergency, may redirect the R&D processes for new drugs, especially in times of pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.